Израел - Енглески - Ministry of Health

kamada ltd, israel - factor ix - powder for solution for injection - factor ix 50 iu/ml - coagulation factor ix, ii, vii and x in combination - treatment and prophylaxis of bleeding in patients with haemophilia b ( congenital factor ix deficiency).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Малта - Енглески - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - factor ii, prothrombin, factor vii, human, factor x, factor ix, protein c - powder and solvent for solution for injection - factor ii (prothrombin) 20-48 iu factor vii, human 10-25 iu factor x, human 22-60 iu factor ix, human 20-31 iu protein c 15-45 iu - antihemorrhagics

Малта - Енглески - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - factor ii, prothrombin, factor vii, human, factor ix, factor x, protein c - powder and solvent for solution for injection - factor ii (prothrombin) 20-48 iu factor vii, human 10-25 iu factor ix, human 20-31 iu factor x, human 22-60 iu protein c 15-45 iu - antihemorrhagics

Израел - Енглески - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - lyophilized powder for injection - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Енглески - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - lyophilized powder for injection - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Енглески - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - lyophilized powder for injection - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Енглески - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - lyophilized powder for injection - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - human coagulation factor ii; human coagulation factor vii; human coagulation factor ix; human coagulation factor x; protein c - powder and solvent for solution for injection - 600 international unit(s) - blood coagulation factors; coagulation factor ix, ii, vii and x in combination - antihemorrhagics, coagulation factors ix, ii, vii and x in combination - treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors, such as a deficiency caused by treatment with vitamin k antagonists or in case of overdose with vitamin k antagonists, when rapid correction of the deficiency is required. treatment and perioperative prophylaxis of hemorrhages in congenital deficiency of vitamin k-dependent coagulation factors, when purified specific coagulation factor concentrate is not available.